Characterization of Late-Onset Citrullinemia 1 in a Korean Patient: Confirmation by Argininosuccinate Synthetase Gene Mutation Analysis

In-Suk Kim, Chang-Seok Ki, Jong-Won Kim, Munhyang Lee, Dong-Kyu Jin and Soo-Youn Lee

1Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea
2Department of Laboratory Medicine, Gyeongsang National University School of Medicine, Jinju 660-701, Korea
3Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea

Received 1 February 2006, Accepted 6 April 2006

A 16-month old boy was referred to our hospital for evaluation of recurrent generalized tonic clonic seizures. Metabolic evaluation revealed significant hyperammonemia (1,112 µg/dl). Amino acid/acylcarnitine screening using tandem mass spectrometry showed markedly increased plasma levels of citrulline (1,350 µM/l) with undetectable levels of arginine and arginosuccinic acid. Urinary excretion of citrulline was markedly increased (38,617 µM/g creatinine). Brain MRI findings showed diffuse high-signal intensity lesions, that involved gray and white matter in both frontal lobes and insula with edematous changes; these findings were consistent with the acute stage of citrullinemia (CTLN). Mutation analysis of the argininosuccinate synthetase (ASS) gene, in this patient, showed a Gly324Ser mutation in exon 13, and a 67-bp duplication mutation in exon 15 (c.1128-6_1188dup67). The patient was confirmed as having late-onset CTLN1 and treated with anticonvulsants, lactulose enema, protein restricted diet and arginine. Here we describe a case of late-onset CTLN1 confirmed by ASS gene mutation identification. This is the first report of a Korean patient with late-onset CTLN1 confirmed by ASS gene mutation identification.

Keywords: Argininosuccinate synthetase (ASS), Citrullinemia, Hyperammonemia, Mass spectrometry, Mutation, Korean

Introduction

Citrullinemia (CTLN), a rare autosomal recessive disorder, is characterized by the accumulation of citrulline and hyperammonemia caused by a deficiency in argininosuccinate synthetase (ASS), the third enzyme in the urea cycle that catalyzes the formation of argininosuccinate from citrulline and aspartate. Patients with CTLN have been classified, biochemically, into three groups: type I, type II and type III on the basis of residual ASS activity, enzyme kinetics and tissue specificity of enzyme deficiency (Saheki et al., 1987). Following the recent report by Kobayashi et al., who identified the citrin gene responsible for adult-onset type II CTLN (Kobayashi et al., 1999), CTLN is now classified as CTLN1 (type I and type III: OMIM #215700, abnormality in ASS gene) and CTLN2 (type II CTLN: OMIM #603471, abnormality in SLC25A13 gene) according to the molecular pathogenesis.

CTLN1 is caused by a mutation in the ASS gene located on chromosome 9q34. CTLN1 presents as a clinical spectrum that includes: a neonatal acute form (the “classic” form), a milder late-onset form, a form with onset of symptoms during pregnancy or postpartum, and a form without symptoms or hyperammonemia (Wick et al., 1973). Most patients with classical CTLN1 present with symptoms during the early neonatal period that include acute hyperammonemia and life-threatening encephalopathy. In other patients, with the milder late-onset type, the disease becomes manifest only later in infancy or in childhood; these patients may have prolonged survival with mental retardation, intermitent ataxia, and abnormalities of hair and skin (Whelan et al., 1976). Women with onset of severe symptoms during pregnancy, or in the postpartum period, have been reported (Guo et al., 2003). Individuals remaining asymptomatic up to at least ten years of age have been reported; it seems possible that they may remain asymptomatic throughout life (Haberle et al., 2002; Haberle et al., 2003).

CTLN2 is caused by citrin deficiency resulting from mutations in SLC25A13 on chromosome 7q21.3, which encodes the mitochondrial solute carrier protein, citrin. Citrin deficiency leads to a failure to shuttle aspartate and glutamate to and from the mitochondrion, leading to a mild
A Korean Late-Onset Citrullinemia 1 Patient

Hyperammonemia and CTLN (Iijima et al., 2001). CTLN2 is characterized by a less pronounced elevation of plasma citrulline and late-onset of clinical symptoms. Affected patients present most commonly with neurological symptoms such as disturbed consciousness, restlessness, and coma that are secondary to chronic cerebral edema. Recently, neonatal presentation of CTLN2 has been reported (Ohura et al., 2001).

Distinction between the clinical forms of CTLN is based on clinical findings; however, they may not be clear-cut. We describe a case of late-onset CTLN1 confirmed by biochemical analyses and ASS gene mutation analysis; this is the first report of a late-onset case of CTLN1 in Korea.

Case report

This male infant is the first child of nonconsanguineous healthy parents. He was born at 40 weeks gestational age by normal spontaneous vaginal delivery. His birth weight was 3,018 g, and Apgar scores were 9 at 1 min and 10 at 5 min. The neonatal period was unremarkable. No specific family history was noted except for a history of hypertension in a grandmother.

At the age of 16 months, he was admitted to a secondary care hospital with recurrent generalized tonic clonic seizures (GTCs) and cyclic vomiting for about 10 days; he was referred to an intensive care unit at a tertiary care hospital. The physical examination was significant for: hypotonia, arm rigidity, ankle clonus and developmental delay. His height and weight were at the 10th and 3rd percentile, respectively. Markedly increased plasma ammonia levels were noted (1,112 µg/dl, normal range; 18–54). Amino acid/acylcarnitine screening using tandem mass spectrometry (MS/MS) was performed. The results of MS/MS showed markedly increased plasma level of citrulline (1,350 µM/l, cut-off <52) with undetectable levels of arginine and arginosuccinic acid (Fig. 1). Plasma amino acid analysis by high performance liquid chromatography (HPLC) showed a high citrulline level (1,709 µM/µl, normal range; 3–35) and a low normal arginine level (42.6 pM/µl, normal range; 12–133). A markedly increased urinary excretion of citrulline (38,617 µM/g creatinine, normal range 22–180) was noted on urinary amino acid analysis. Urinary organic acid analysis by GC/MS showed increased urinary orotic acid excretion (297.15 mM/M creatinine, normal range; 0–7.64). The brain MRI revealed diffuse high-signal intensity lesions involving gray and white matter in both the frontal lobes and insula with edematous changes (Fig. 2). These findings were consistent with the acute stage of CTLN. Electroencephalography (EEG) showed no specific findings.
We collected blood for DNA analysis from the patient and his parents. Mutation analysis using PCR, and direct sequencing of all exons and adjacent introns of the ASS gene were performed. The patient had a Gly324Ser mutation in exon 13 and a 67-bp duplication mutation in exon 15. Gly324Ser mutation was observed in the patient and his father and 67-bp duplication mutation was noted in the patient and his mother. (A. c.970G > A (p.Gly324Ser) mutation in the patient and his father; B. 67-bp duplication mutation in exon 15 (c.1128-6_1188dup67) in the patient and his mother).

![Fig. 3. Argininosuccinate synthetase gene mutation analysis showed Gly324Ser mutation in exon 13 and 67-bp duplication mutation in exon 15. Gly324Ser mutation was observed in the patient and his father and 67-bp duplication mutation was noted in the patient and his mother. (A. c.970G > A (p.Gly324Ser) mutation in the patient and his father, B. 67-bp duplication mutation in exon 15 (c.1128-6_1188dup67) in the patient and his mother).](image)

Discussion

Classical neonatal-onset CTLN1 is suspected in infants on a normal unrestricted protein diet, and who present in the first week of life with: hyperammonemia resulting in increasing lethargy, somnolence, refusal to feed, vomiting, and tachypnea; or increased intracranial pressure (secondary to hyperammonemia) resulting in: increased neuromuscular tone, spasticity, ankle clonus seizures, loss of consciousness, and death (Bachmann, 2003a; Bachmann, 2003b). Fifty-six percent of individuals with classic CTLN1 are symptomatic within four days of age, and 67% within one week of age (Bachmann, 2003a). The longest reported survival of an untreated infant with classic CTLN1 was 17 days (Thoen et al., 1977). Late-onset CTLN1 is suspected in individuals with recurrent lethargy, somnolence, mental retardation, and chronic or recurrent hyperammonemia. When episodes of hyperammonemia occur, the findings are similar to those seen in the acute neonatal form; however, the neurologic findings may be more subtle because of the older age of affected individuals. The symptoms of hyperammonemia are often non-specific, and may not be recognized by the family or primary care physician in a timely manner for early intervention. Patients with CTLN2 show hyperammonemia and neuropsychiatric symptoms such as: disorientation, delirium, aberrant behavior, delusion, and disturbance of consciousness, often leading rapidly to death (Kohnoyshi et al., 1995). The onset is sudden, usually between the ages of 20 and 40 years (Ikeda et al., 2001). Although the prognosis is generally poor, liver transplantation can be remarkably effective (Kawamoto et al., 1997; Ikeda et al., 2001). Generally, the clinical course of individuals with CTLN2 is milder than CTLN1, frequently distinguishing it from late-onset CTLN1. It is unclear why CTLN2 has milder symptoms and later onset than late-onset CTLN1; distinguishing between these two disorders can be difficult.

The diagnostic findings in the patient described here were consistent with CTLN. The detection of a mutation in the ASS gene, the biochemical profile and the presenting symptoms excluded CTLN2 derived from citrin deficiency. Molecular...
Approximately 31,000 newborns and high-risk infants have been tested, as a result of the newborn screening program, using MS/MS at a commercial laboratory center in Korea, and 28 infants (0.09%) were confirmed to have an inborn error of metabolism (Yun et al., 2003). Of the 28 infants, only one (0.003%) infant was reported to have CTLN. The screening results allow for the introduction of immediate specific treatment for CTLN, and may have prevented metabolic decompensation in newborns with presumed mild CTLN1. Although the incidence of CTLN is very low in Korea, MS/MS screening, for CTLN, may improve the cost per quality-adjusted life years saved by mass screening programs.

CTLNI is inherited in an autosomal recessive manner. The parents of an affected child are obligate heterozygotes and asymptomatic carriers. Therefore mutation analysis is the method required for confirmation of a definite diagnosis in affected patients, carrier detection in parents and prenatal diagnosis for subsequent pregnancies. Currently there are 58 different ASS gene mutations: seven deletion, four splice site, two duplication, two nonsense and 43 missense that have been identified. Three mutations are particularly frequent: IVS6-2A > G, Gly390Arg, and Arg304Trp (Gao et al., 2003). Most of the described mutations, in the ASS gene, are missense mutations; however, patients have highly variable clinical

### Table 1. Reported citrullinemia in Korea

<table>
<thead>
<tr>
<th>Case number</th>
<th>Year reported</th>
<th>Onset of symptoms</th>
<th>Initial symptoms</th>
<th>Highest citrulline level</th>
<th>Highest ammonia level</th>
<th>Molecular test of ASS gene</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1987</td>
<td>26-day-old</td>
<td>Vomiting, seizure, coma</td>
<td>3.150 µM/l (normal range: 20-50)</td>
<td>500 µg/dl NT</td>
<td>Neurologic deficit (Kim et al., 1987)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1995</td>
<td>3-day-old</td>
<td>Dyspnea, seizure, coma</td>
<td>571 µM/l (normal range: 13-42)</td>
<td>737 µg/dl NT</td>
<td>Death (Park et al., 1995)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1997</td>
<td>3-day-old</td>
<td>Lethargy, seizure, coma</td>
<td>2.599 µM/l (normal range: 0-13)</td>
<td>400 µg/dl NT</td>
<td>Death (Park et al., 1997)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>1999</td>
<td>3-month-old</td>
<td>Convulsions</td>
<td>2.401 µM/l (normal range: 3-35)</td>
<td>400 µg/dl NT</td>
<td>Neurologic deficit (Kim et al., 1999)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>1999</td>
<td>53-day-old</td>
<td>Convulsions, drowsy mentality</td>
<td>1.376 µM/l (normal range: 3-35)</td>
<td>535 µg/dl NT</td>
<td>Death (Kim et al., 1999)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>1999</td>
<td>9-day-old</td>
<td>Feeding difficulty, lethargy</td>
<td>4.178 µM/l (normal range: 13.8-41.6)</td>
<td>400 µg/dl NT</td>
<td>Neurologic deficit (Jeong et al., 1999)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>2000</td>
<td>Not described</td>
<td>Not described</td>
<td>Not described</td>
<td>[p.Gly324Ser]+ [c. IVS6-2A&gt;G]</td>
<td>Death (Hong et al., 2000c)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>2000</td>
<td>Not described</td>
<td>Not described</td>
<td>Not described</td>
<td>[c.1128-6_1188dup67]+ [c. IVS6-2A&gt;G]</td>
<td>Neurologic deficit (Hong et al., 2000c)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>2000</td>
<td>Not described</td>
<td>Not described</td>
<td>Not described</td>
<td>[p.Gly324Ser]+ [c. IVS6-2A&gt;G]</td>
<td>Death (Hong et al., 2000c)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>2002</td>
<td>3-day-old</td>
<td>Drowsy mentality</td>
<td>1.708 µg/dl (normal range: 13-42)</td>
<td>1,708 µg/dl NT</td>
<td>Death (Song et al., 2002)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>2002</td>
<td>55-year-old</td>
<td>Generalized weakness, insomnia</td>
<td>3.958 µM/l (normal range: 15-50.5)</td>
<td>427 µg/dl NT</td>
<td>Neurologic deficit (Park et al., 2002)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>2006</td>
<td>16-month-old</td>
<td>Seizure, vomiting</td>
<td>1.709 µM/l (normal range: 3-35)</td>
<td>1,112 µg/dl NT</td>
<td>This case</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ASS, argininosuccinate synthetase gene; NT, not tested.
courses. The clinical course of patients with in-frame mutations or the Gly390Arg mutation generally is the early-onset/severe presentation. In mutation analyses performed on three Korean patients with CTLN, all three patients were compound heterozygotes (Hong et al., 2000c). They had splice mutation IVS6-2A > G; two of the patients had a Gly324Ser mutation in exon 15, and one had a 67-bp duplication mutation in exon 15 (c.1128-6_1188dup67). Molecular prenatal diagnosis has been successfully performed for a family with CTLN1 in Korea (Hong et al., 2000b). In the current study, the patient was compound heterozygotes. As might be expected, for asymptomatic carriers, his parents each had a different mutant allele. One mutant allele inherited from his father was the Gly324Ser mutation, and the other from his mother was the 67-bp duplication mutation in exon 15. The missense mutation, Gly324Ser (substitution of serine for glycine), involved conversion of a CpG dinucleotide in the sense strand to Cpa. It has already been described in patients with the classical form of CTLN (Kobayashi et al., 1990; Hong et al., 2000b; Gao et al., 2003) with a mild clinical course (Huberle et al., 2003). The 67-bp duplication mutation in exon 15, duplication of 67-bp (from +6 of intron 14 to 5′-side 61-bp of exon 15) causes a frameshift duplication mutation in exon 15, duplication of 67-bp (from -6 of intron 14 to 5′-side 61-bp of exon 15) causes a frameshift in exon 15 leading to premature termination. This mutation has been reported previously in one Korean patient with CTLN1 that typically presents with hyperammonemia, metabolic coma, mental retardation, and/or early death (Hong et al., 2000a; Hong et al., 2000c). It continues to be difficult to show a genotype-phenotype correlation, because many patients have been compound heterozygotes, from different environments at the time of diagnosis, and/or had several different treatment regimes at various stages of disease. Although a limited number of Korean patients have been studied, the IVS6-2A > G; Gly324Ser, 67-bp duplication mutation in exon 15 appears to be the most common mutation in the ASS gene found in Korea to date. Molecular investigation improves our understanding of the pathogenesis of CTLN by identifying the most frequent mutant alleles in Korean patients. In addition, availability of molecular prenatal diagnosis and carrier detection may help families prevent neurologic sequela and/or early death associated with CTLN.

In conclusion, we describe a case of late-onset CTLN1 confirmed by biochemical and ASS gene mutation analysis. This is the first report of a patient with late-onset CTLN1, not acute neonatal onset CTLN1, in Korea. Therefore, this case report shows the importance of performing molecular investigations in order to reach a definitive diagnosis, particularly in cases of late-onset CTLN.

References


deficiency and high carrier rates in Asian populations. Mol. Genet. Metab. 80, 356-359.